Ondine Biomedical’s Steriwave Technology Proves Effective Against Drug-Resistant Fungus

The latest announcement is out from Ondine Biomedical, Inc. ( (GB:OBI) ).

Ondine Biomedical Inc. has announced that its Steriwave photodisinfection technology is 99.9% effective against the drug-resistant fungus C. auris, which has seen a 67% increase in cases in EU hospitals over the last year. This development is significant as C. auris poses a major threat to healthcare systems due to its resistance to most disinfectants and high mortality rate, with the potential to incur substantial costs in containment and treatment. Ondine’s technology offers a promising solution to manage the rising burden of invasive fungal infections, which have become a growing public health concern worldwide.

The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.

More about Ondine Biomedical, Inc.

Ondine Biomedical is a global leader in photodisinfection technology, dedicated to delivering innovative solutions to combat antimicrobial resistance and healthcare-associated infections. With proven success in reducing pathogen transmission and outbreaks, Ondine remains at the forefront of preventing infectious disease threats in hospitals worldwide.

Average Trading Volume: 391,899

Technical Sentiment Signal: Buy

Current Market Cap: £79.05M

For detailed information about OBI stock, go to TipRanks’ Stock Analysis page.